A Retrospective Study of Transbronchial Cryobiopsy in the Diagnosis of Progressive Pulmonary Fibrosis

Launched by CHINA-JAPAN FRIENDSHIP HOSPITAL · Feb 17, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a procedure called transbronchial cryobiopsy (TBLC) to see how well it helps doctors diagnose progressive pulmonary fibrosis, a condition that causes scarring in the lungs and makes it hard to breathe. The study aims to understand how effective and safe this procedure is, as well as what factors might influence its success. The trial is currently not recruiting participants, but it will involve adults aged 18 and older who have specific health criteria, such as a certain level of lung function and recent imaging tests.

To be eligible for the study, participants need to have progressive pulmonary fibrosis and meet specific health requirements, including a body mass index (BMI) below 35 and certain lung function test results. Unfortunately, those with low platelet counts or certain blood clotting issues won't be able to participate. If selected, participants can expect to undergo TBLC, which is a type of lung biopsy that uses cold to remove small pieces of lung tissue for testing. This study could provide valuable insights into better diagnosing and managing this challenging lung condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with PPF, ≥18 years of age, unclassified ILD, HRCT ≤3 months, forced vital capacity (FVC)≥50% predicted value, pulmonary carbon monoxide diffusion (DLCO)≥35% predicted value, echocardiography ≤12 months, estimated pulmonary systolic blood pressure ≤40 mmHg, Body mass index (BMI)≤35 kg/m2.
• Exclusion Criteria:
• • Patients with platelet counts below 50,000e+9/L or International Normalized ratio of prothrombin time (INR) above 1.5 are not eligible for TBLC